This is a fully human IgG4 antibody using the same sequences as the therapeutic antibody dupilumab. It specifically binds to the alpha subunit of IL4 receptor, thereby functioning as a receptor antagonist. Dupilumab effectively inhibits IL4 signaling through Type I receptor (IL4Rα/γc), as well as both IL4 and IL13 signaling through Type II receptor (IL4Rα/IL13Rα). Ultimately, it downregulates Type-2 inflammation and immune function. Dupilumab, commercially known as Dupixent, is available in a subcutaneous injection formulation. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. Dupilumab can be utilized either as monotherapy or in combination with other drugs such as corticosteroids.